• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2001-2019 年欧洲肺动脉高压死亡率。

Mortality from pulmonary hypertension in Europe 2001-2019.

机构信息

National Heart and Lung Institute, Imperial College, Hammersmith Hospital, London, UK.

Medical Data Research Collaborative, London, UK.

出版信息

BMC Pulm Med. 2024 Aug 28;24(1):415. doi: 10.1186/s12890-024-03235-y.

DOI:10.1186/s12890-024-03235-y
PMID:39198769
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11351198/
Abstract

BACKGROUND

The incidence of Pulmonary Hypertension (PH) and Pulmonary Arterial Hypertension (PAH) is believed to be on the rise and is associated with poor outcomes.

METHODS

We extracted age-standardized mortality rates (ASMRs) for decedents ≥ 18 years of age from the World Health Organization Mortality Database, using International Classification of Diseases 10th edition codes for PH and PAH, covering the period from 2001 to 2019. The UK and European Union countries with at least 1,000,000 inhabitants and at least 75% of available data points over the study period were included.

RESULTS

Between 2001 and 2019, in countries with available data, the median ASMR for PH increased by + 1.19 per 1,000,000 (+ 22.51%) in females and + 0.36 per 1,000,000 (+ 6.06%) in males. Out of 19 countries, 13 demonstrate an increase in female PH ASMR, and 12 reported an increase in male PH ASMR. In contrast, median PAH ASMR decreased by -0.29 per 1,000,000 (-28.74%) in females and remained relatively unchanged in males, with a minor increase of + 0.01 per 1,000,000 (+ 1.07%). Notably, there was significant inter-country heterogeneity, with countries such as Hungary, Romania, and Poland displaying results incongruous with the rest of Europe.

CONCLUSIONS

While publicly available mortality statistics for PH may be unreliable, these data suggest an overall increase in mortality across Europe from 2001 to 2019. However, mortality from PAH has shown a decrease in females and a modest increase in males. This underscores the urgent need for robust and high-quality mortality reporting, including international registries, for both PH and PAH.

摘要

背景

肺动脉高压(PH)和肺动脉高血压(PAH)的发病率据信呈上升趋势,并与不良预后相关。

方法

我们从世界卫生组织死亡率数据库中提取了年龄标准化死亡率(ASMR),使用第 10 版国际疾病分类代码为 PH 和 PAH 的死者年龄≥18 岁,涵盖了 2001 年至 2019 年期间。包括英国和欧盟国家,这些国家的居民至少有 100 万,并且在研究期间至少有 75%的数据点可用。

结果

在有数据的国家,2001 年至 2019 年间,女性 PH 的中位 ASMR 增加了+1.19/100 万(+22.51%),男性 PH 的中位 ASMR 增加了+0.36/100 万(+6.06%)。在 19 个国家中,有 13 个国家的女性 PH ASMR 增加,有 12 个国家报告男性 PH ASMR 增加。相比之下,女性 PAH 的中位 ASMR 下降了-0.29/100 万(-28.74%),而男性相对不变,仅略有增加+0.01/100 万(+1.07%)。值得注意的是,存在显著的国家间异质性,匈牙利、罗马尼亚和波兰等国的结果与欧洲其他国家不一致。

结论

虽然公开的 PH 死亡率统计数据可能不可靠,但这些数据表明,2001 年至 2019 年期间,欧洲的总体死亡率有所上升。然而,PAH 的死亡率在女性中有所下降,在男性中略有增加。这突显出迫切需要为 PH 和 PAH 建立稳健和高质量的死亡率报告,包括国际登记处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad03/11351198/c13becc69599/12890_2024_3235_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad03/11351198/c67c2e16c681/12890_2024_3235_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad03/11351198/c13becc69599/12890_2024_3235_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad03/11351198/c67c2e16c681/12890_2024_3235_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad03/11351198/c13becc69599/12890_2024_3235_Fig2_HTML.jpg

相似文献

1
Mortality from pulmonary hypertension in Europe 2001-2019.2001-2019 年欧洲肺动脉高压死亡率。
BMC Pulm Med. 2024 Aug 28;24(1):415. doi: 10.1186/s12890-024-03235-y.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Phosphodiesterase type 5 inhibitor plus endothelin receptor antagonist compared to either alone for group 1 pulmonary arterial hypertension.与单独使用相比,5型磷酸二酯酶抑制剂加内皮素受体拮抗剂用于1型肺动脉高压的治疗
Cochrane Database Syst Rev. 2025 Aug 4;8(8):CD015824. doi: 10.1002/14651858.CD015824.pub2.
4
Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism.性别作为急性症状性肺栓塞成年患者死亡率的一个预后因素。
Cochrane Database Syst Rev. 2025 Mar 20;3(3):CD013835. doi: 10.1002/14651858.CD013835.pub2.
5
Increasing Trends of Pediatric Thoracic and Lumbar Spine Fractures in the United States from 2004 to 2023: A 20-year National Injury Review Depicting Shifts in Mechanisms of Injury.2004年至2023年美国儿童胸腰椎骨折的增长趋势:一项为期20年的全国性损伤回顾,描绘损伤机制的变化
Clin Orthop Relat Res. 2025 Feb 25. doi: 10.1097/CORR.0000000000003421.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
7
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.
8
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
9
Interventions targeted at women to encourage the uptake of cervical screening.针对女性的干预措施,以鼓励她们接受宫颈癌筛查。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3.
10
Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults.经胸多普勒超声心动图用于检测成人肺动脉高压。
Cochrane Database Syst Rev. 2022 May 9;5(5):CD012809. doi: 10.1002/14651858.CD012809.pub2.

引用本文的文献

1
Global Burden of Pediatric Pulmonary Arterial Hypertension, 1990-2021: A Systematic Analysis from the Global Burden of Disease Study 2021.1990 - 2021年全球儿童肺动脉高压负担:来自《2021年全球疾病负担研究》的系统分析
Pediatr Cardiol. 2025 Aug 29. doi: 10.1007/s00246-025-04009-x.

本文引用的文献

1
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237.
2
Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.先天性心脏病成人患者肺动脉高压的药物治疗:国际COMPERA-CHD注册研究的更新与扩展结果
Cardiovasc Diagn Ther. 2021 Dec;11(6):1255-1268. doi: 10.21037/cdt-21-351.
3
Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
COPD 患者的肺动脉高压:来自新发起的肺动脉高压治疗比较前瞻性登记研究(COMPERA)的结果。
Chest. 2021 Aug;160(2):678-689. doi: 10.1016/j.chest.2021.02.012. Epub 2021 Feb 11.
4
Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.特发性肺纤维化相关肺动脉高压患者应用吸入曲前列尼尔治疗
N Engl J Med. 2021 Jan 28;384(4):325-334. doi: 10.1056/NEJMoa2008470. Epub 2021 Jan 13.
5
Characterization of Patients with Pulmonary Arterial Hypertension: Data from the Polish Registry of Pulmonary Hypertension (BNP-PL).肺动脉高压患者的特征:来自波兰肺动脉高压登记处(BNP-PL)的数据。
J Clin Med. 2020 Jan 8;9(1):173. doi: 10.3390/jcm9010173.
6
The revised definition of pulmonary hypertension: exploring the impact on patient management.肺动脉高压的修订定义:探索对患者管理的影响。
Eur Heart J Suppl. 2019 Dec;21(Suppl K):K4-K8. doi: 10.1093/eurheartj/suz211. Epub 2019 Dec 17.
7
Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations.从肺动脉高压登记研究中学习:陷阱和建议。
Eur Respir Rev. 2019 Dec 18;28(154). doi: 10.1183/16000617.0050-2019. Print 2019 Dec 31.
8
Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada.世界卫生组织1至4组肺动脉高压的发病率和患病率不断上升:加拿大安大略省的一项基于人群的队列研究。
Circ Cardiovasc Qual Outcomes. 2018 Feb;11(2):e003973. doi: 10.1161/CIRCOUTCOMES.117.003973.
9
Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.马西替坦治疗不可手术的慢性血栓栓塞性肺动脉高压(MERIT-1):来自多中心、2 期、随机、双盲、安慰剂对照研究的结果。
Lancet Respir Med. 2017 Oct;5(10):785-794. doi: 10.1016/S2213-2600(17)30305-3. Epub 2017 Sep 11.
10
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).2015年欧洲心脏病学会(ESC)/欧洲呼吸学会(ERS)肺动脉高压诊断和治疗指南:欧洲心脏病学会(ESC)和欧洲呼吸学会(ERS)肺动脉高压诊断和治疗联合工作组:得到以下组织认可:欧洲儿科和先天性心脏病协会(AEPC)、国际心肺移植学会(ISHLT)。
Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29.